StockData
Kiora Pharmaceuticals Inc logo

Kiora Pharmaceuticals Inc (KPRX) stock

KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.93−0.05 (-5.30%)

Close on Nov 17, 2026Market cap $4.11MP/E –Yield –

Kiora Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Kiora Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.86M, up 6.8% year over year. For fiscal 2025 it was $10.78M, up 37.5% from the year before. Over ten years it grew 14.8% a year on average. The highest annual figure on record is $10.78M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.78M+37.5%
FY2024Dec 31, 2024$7.84M+94.7%
FY2023Dec 31, 2023$4.03M+16.8%
FY2022Dec 31, 2022$3.45M-35.5%
FY2021Dec 31, 2021$5.35M+50.0%
FY2020Dec 31, 2020$3.57M-33.8%
FY2019Dec 31, 2019$5.39M-33.1%
FY2018Dec 31, 2018$8.06M-22.0%
FY2017Dec 31, 2017$10.33M+22.7%
FY2016Dec 31, 2016$8.42M+210.0%
FY2015Dec 31, 2015$2.72M+411.6%
FY2014Dec 31, 2014$531.12K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.08M-19.8%
Q1 FY2026Mar 31, 2026$2.12M-16.1%
Q4 FY2025Dec 31, 2025$2.93M+52.2%
Q3 FY2025Sep 30, 2025$2.73M+24.9%
Q2 FY2025Jun 30, 2025$2.59M+26.4%
Q1 FY2025Mar 31, 2025$2.53M+50.3%
Q4 FY2024Dec 31, 2024$1.92M+73.1%
Q3 FY2024Sep 30, 2024$2.18M+101.4%
Q2 FY2024Jun 30, 2024$2.05M+47.2%
Q1 FY2024Mar 31, 2024$1.68M+284.3%
Q4 FY2023Dec 31, 2023$1.11M+32.1%
Q3 FY2023Sep 30, 2023$1.09M-18.6%
Q2 FY2023Jun 30, 2023$1.39M+145.4%
Q1 FY2023Mar 31, 2023$438.28K-38.1%
Q4 FY2022Dec 31, 2022$841.62K-16.0%
Q3 FY2022Sep 30, 2022$1.33M-18.2%
Q2 FY2022Jun 30, 2022$567.23K-60.6%
Q1 FY2022Mar 31, 2022$707.93K-44.7%
Q4 FY2021Dec 31, 2021$1.00M-0.9%
Q3 FY2021Sep 30, 2021$1.63M+65.2%
Q2 FY2021Jun 30, 2021$1.44M+128.2%
Q1 FY2021Mar 31, 2021$1.28M+36.5%
Q4 FY2020Dec 31, 2020$1.01M-32.5%
Q3 FY2020Sep 30, 2020$985.88K-59.0%
Q2 FY2020Jun 30, 2020$631.11K-17.4%
Q1 FY2020Mar 31, 2020$938.04K+30.0%
Q4 FY2019Dec 31, 2019$1.50M+4.2%
Q3 FY2019Sep 30, 2019$2.41M+6.5%
Q2 FY2019Jun 30, 2019$763.90K-58.4%
Q1 FY2019Mar 31, 2019$721.48K-71.4%
Q4 FY2018Dec 31, 2018$1.44M-53.3%
Q3 FY2018Sep 30, 2018$2.26M-28.9%
Q2 FY2018Jun 30, 2018$1.84M-18.8%
Q1 FY2018Mar 31, 2018$2.52M+38.9%
Q4 FY2017Dec 31, 2017$3.08M+19.4%
Q3 FY2017Sep 30, 2017$3.18M+29.7%
Q2 FY2017Jun 30, 2017$2.26M–
Q1 FY2017Mar 31, 2017$1.82M–
Q4 FY2016Dec 31, 2016$2.58M–
Q3 FY2016Sep 30, 2016$2.45M–

More Kiora Pharmaceuticals figures

See a number that looks wrong?